Why cancer patients suffer weight loss and how to stop it
Wasting syndrome – a deadly cancer side-effect – might be diagnosed and treated early on, according to a new study.
Wasting syndrome – a deadly cancer side-effect – might be diagnosed and treated early on, according to a new study.
Scientists achieve 80% survival rate in animals using a protein as an alternative to traditional treatments.
Israeli synthetic biologist helps a US startup design switches that engineer immune cells right inside the body for faster, less expensive treatment.
5 years after surgery, cancer spread in 12.5% of patients who got drugs for anxiety, pain and inflammation, compared to 50% in control group.
Combination of ultrasound and nanobubbles enables specific targeting and minimizes damage to surrounding tissue.
Study finds that high-intensity aerobic workouts prevent cancer from spreading by making less glucose available to the tumor.
Israeli study shows stress-reduction technique boosts emotional wellbeing of breast and ovarian cancer gene carriers.
Researcher finds out how deadly skin cancer passes the blood-brain barrier and tests a treatment that delays spread of the metastases by up to 80%.
After a computer scientist’s mom got ovarian cancer, he started a company using AI to find biomarkers in biopsy images and give personalized guidance.
OncoHost’s prediction platform is geared to help physicians choose the best chemo or immunotherapy for each patient, rather than the hit and miss ‘one size fits all.’
An Israeli startup led by a former commander of the IDF’s canine unit has raised $6.2m to develop early cancer detection screening centers staffed by Labradors.
Israeli and Portuguese researchers develop tiny synthetic molecules that can penetrate less accessible areas of tumors and could be taken orally.
NeoTX, whose team includes several Nobel laureates, is testing a cancer-fighting approach that uses bacteria to bait the immune system into an attack.
Bonus BioGroup’s MesenCure drug shown to lower the inflammatory overreaction in cancer patients that can cause multisystem failure.
Technion scientists propose new framework for cancer research based on apparent capacity of cancer cells to learn and adapt.